Medical Developments International (ASX:MVP) has reported a steady first-half performance for the financial year 2026, with growth in its flagship pain relief product helping to underpin revenue and cash flow despite softer conditions in its respiratory business.

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

The life sciences sector will come together in March 2026 for a major show of support for women’s leadership, as AusBiotech and Medicines Australia expand their partnership to deliver both the long-running Women in Life Sciences Luncheon and, for the first time, a dedicated Leadership Summit.

Botanix Pharmaceuticals (ASX:BOT) has taken a major step to strengthen its commercial momentum and long-term manufacturing strategy, securing commitments for approximately $45 million in fresh capital as it looks to expand production, stabilise supply and accelerate growth of its lead dermatology product, Sofdra.

Remuneration for board directors in Australia’s listed healthcare and biotechnology sector increased materially in the financial year 2025, with growth driven largely by the expanding use of equity-based incentives rather than increases in base fees, according to a new sector analysis by specialist executive and board search firm Wexford Hayes.

Chimeric Therapeutics has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh.

A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care.

Emyria’s (ASX:EMD) push to scale its insurer-backed mental health services across Australia has taken a significant step forward, with Medibank expanding its funding agreement to support patients at the company’s new Mornington Peninsula clinic in Victoria.

CSL has reported a slip in first-half results for 2026, shaped by policy headwinds, restructuring charges and asset impairments, even as the company accelerates a wide-ranging transformation aimed at restoring growth and long-term value.

The therapeutic antibody developer Patrys (ASX:PAB) has announced the appointment of Dr Samantha South as its new Chief Executive Officer, effective 16 February 2026.

Amplia Therapeutics (ASX:ATX) has taken a step forward in its clinical expansion strategy, announcing the opening of two U.S. trial sites for its AMPLICITY pancreatic cancer study.

A new peer-reviewed study published in PLOS One has provided evidence that pentosan polysulfate sodium delivers sustained clinical, functional, and structural benefits in osteoarthritis, reinforcing its potential as a disease-modifying therapy.

Chimeric Therapeutics (ASX:CHM) has announced that its CHM CDH17 CAR-T program has advanced to Dose Level 3. This is the highest dose tier in the Phase 1 portion of its ongoing trial.

Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.

Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.

Algorae Pharmaceuticals (ASX:1AI) has taken another step in building a diversified commercial medicines platform, finalising a new licensing and supply agreement that broadens its reach beyond oncology into cardiovascular and metabolic disease markets.